No, Snorting Miralax Does Not Cause Low White Blood Cell Count
Snorting Miralax (polyethylene glycol 3350) will not cause low white blood cell counts based on the available evidence. Miralax is an osmotic laxative intended for oral use only, and there is no documented mechanism or clinical evidence linking its use—whether oral or via nasal insufflation—to leukopenia or bone marrow suppression 1.
Why This Question Arises
This concern likely stems from confusion with medications that genuinely cause myelosuppression. The evidence provided discusses multiple drugs that do cause low WBC counts, but none of these are Miralax:
- Clozapine causes agranulocytosis in ~1% of patients and requires WBC monitoring with baseline counts ≥3,500/mm³ 2
- TMP-SMX can cause leukopenia and thrombocytopenia, with incidence varying from <0.1% to 12-34% depending on the population 3
- Azathioprine requires dose reduction if WBC falls below 4,000/mm³ 4, 5
- Hydroxyurea can cause neutropenia requiring monitoring 6
What the Evidence Shows About Miralax
Safety Profile
The FDA labeling for Miralax lists it as an osmotic laxative for occasional constipation, with no warnings about hematologic effects 1.
Research Findings
- Inhalation studies in rats: When PEG 3350 was deliberately aerosolized and inhaled at concentrations up to 1008 mg/m³ for 2 weeks, the only hematologic finding was a 50% increase (not decrease) in neutrophil counts in males at the highest dose 7
- Long-term oral use: A 12-month study of 311 patients (including 117 elderly patients) showed no clinically significant changes in hematology or blood chemistry 8
- Pediatric studies: Research examining behavioral effects in mice found no hematologic abnormalities 9
Important Clinical Caveats
Misuse Concerns
Snorting Miralax is dangerous for entirely different reasons:
- It is not designed for nasal administration
- Nasal insufflation of any powder can cause local tissue damage, inflammation, and infection
- One case report documented potential ethylene glycol contamination in generic PEG 3350 causing acute kidney injury and metabolic acidosis 10—though this was from oral ingestion, nasal administration of contaminated product could theoretically be even more dangerous
When to Actually Worry About Low WBC
If a patient presents with low WBC and reports Miralax use (snorted or otherwise), look for:
- Concurrent medications that genuinely cause myelosuppression (chemotherapy, immunosuppressants, clozapine, carbamazepine)
- Underlying hematologic disorders
- Infections causing bone marrow suppression
- Nutritional deficiencies (B12, folate)
The Miralax is a red herring in this clinical scenario.
Bottom Line
The evidence is clear: Miralax does not cause low white blood cell counts. If a patient has leukopenia and has been using Miralax (regardless of route), the cause lies elsewhere. Focus your diagnostic workup on actual causes of myelosuppression rather than attributing it to polyethylene glycol 3350 exposure.